- Home
- HQL
as 04-18-2025 1:37pm EST
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 368.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 120.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.34 - $14.37 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 15 '25 | Sell | $11.92 | 1,700 | $20,264.00 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 10 '25 | Sell | $11.14 | 30,156 | $335,937.84 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 3 '25 | Sell | $11.90 | 17,210 | $205,931.56 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Apr 1 '25 | Sell | $12.36 | 46,723 | $576,754.01 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Mar 31 '25 | Sell | $12.58 | 48,623 | $611,677.34 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Mar 27 '25 | Sell | $12.98 | 36,524 | $474,961.12 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Mar 24 '25 | Sell | $13.21 | 2,329 | $30,766.09 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Feb 26 '25 | Sell | $13.62 | 200 | $2,724.00 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Feb 13 '25 | Sell | $13.88 | 100 | $1,388.00 | 3,077,216 | |
| Saba Capital Management, L.P. | HQL | 10% Owner | Feb 12 '25 | Sell | $13.75 | 36,536 | $502,370.00 | 3,077,216 |
Latest abrdn Life Sciences Investors Shares of Beneficial Interest News
HQL Breaking Stock News: Dive into HQL Ticker-Specific Updates for Smart Investing
ACCESS Newswire
18 days ago
Aberdeen U.S. Closed-End Funds Announce Distribution Payment Details
ACCESS Newswire
2 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
3 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
5 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
7 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
8 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
10 months ago
abrdn U.S. Closed-End Funds Announce Distribution Payment Details
ACCESSWIRE
10 months ago
abrdn Life Sciences Investors (HQL) Announces Results of Annual Meeting of Shareholders
Compare HQL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HQL abrdn Life Sciences Investors Shares of Beneficial Interest - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.